Abstract:The prostaglandins are lipid mediators, discovered in the 1930s by von Euler in Sweden and Goldblatt in the United Kingdom. They are made by the bifunctional enzyme, cyclooxygenase, which has both cyclooxygenase and peroxidase activities in the same molecule. Prostaglandins are involved in physiological functions such as protection of the stomach mucosa, aggregation of platelets and regulation of kidney function. They also have pathological functions such as their involvement in inflammation, fever and pain. Vane in 1971 elegantly showed that the pharmacological actions of aspirin and similar drugs were due to the inhibition of cyclooxygenase. Thus, aspirin-like drugs exert their anti-inflammatory, antipyretic and analgesic effects by inhibition of cyclooxygenase. In 1991, Simmons and his colleagues identified a second cyclooxygenase enzyme, designated cyclooxygenase-2, derived from a separate gene from cyclooxygenase-1. Cyclooxygenase-2 is upregulated by inflammatory mediators and forms prostaglandins which intensify the inflammatory response. Cyclooxygenase-1 is, therefore, a 'housekeeping' enzyme making prostaglandins, which are important for maintaining physiological functions and cyclooxygenase-2 makes prostaglandins which are important in inflammation. The discovery of cyclooxygenase-2 and the establishment of its structure led to the development of selective inhibitors of this enzyme, such as celecoxib and rofecoxib, with potent anti-inflammatory actions but with reduced gastrotoxic effects. A putative cyclooxygenase-3, has also been characterised and cloned. This enzyme is a product of the cyclooxygenase-1 gene, but retains intron 1 after transcription and translates into a cyclooxygenase enzyme with 34 additional amino acids. It is more sensitive to inhibition by paracetamol, aspirin and some other non-steroid anti-inflammatory drugs than cyclooxygenase-1 or cyclooxygenase-2. A cyclooxygenase enzyme induced in cultured cells by some non-steroid anti-inflammatory drugs is also more sensitive to inhibition by paracetamol than cyclooxygenase-2 induced by bacterial lipopolysaccharide.

Prostaglandin biosynthesis can be triggered by lipid peroxides

Constraints on prostaglandin biosynthesis in tissues.

Adaptive response induced by lipid peroxidation products in cell cultures.

Prostanoids in health and disease

Effects of nitric oxide and nitric oxide‐derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis

[Effect of Lipopolysaccharide of Porphyromonas Gingivalis on Prostaglandin E2 Biosynthetic Pathway in Human Monocytic Cell Strain THP-1].

Comparison of branched-chain and tightly coupled reaction mechanisms for prostaglandin H synthase.

Thiol antioxidant and thiol-reducing agents attenuate 15-deoxy-delta 12,14-prostaglandin J2-induced heme oxygenase-1 expression

Interaction of electrophilic lipid oxidation products with mitochondria in endothelial cells and formation of reactive oxygen species

Inhibition of prostaglandin biosynthesis by eicosapentaenoic acid

Mechanism for the reactivation of the peroxidase activity of human cyclooxygenases: investigation using phenol as a reducing cosubstrate

Prostaglandins and Inflammation

Inhibitors of cyclooxygenases: mechanisms, selectivity and uses

Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation

Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein.

Profiling oxylipins released from human platelets activated through the GPVI collagen receptor

Hydrogen peroxide mediates pro-inflammatory cell-to-cell signaling: a new therapeutic target for inflammation?

A cyclooxygenase-2-dependent prostaglandin E2 biosynthetic system in the Golgi apparatus

Modulation of Enzyme-Catalyzed Synthesis of Prostaglandins by Components Contained in Kidney Microsomal Preparations

Human CYP2S1 metabolizes cyclooxygenase- and lipoxygenase-derived eicosanoids

Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis